Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

We carried out a systematic review and meta-analysis to assess the efficacy and safety of imidafenacin for treating overactive bladder in adult.

Methods

A literature review was performed to identify all published randomized placebo-controlled trials of imidafenacin for the treatment of OAB. The search included the following databases: MEDLINE, EMBASE. The reference lists of retrieved studies were also investigated.

Results

Five publications involving a total of 1,428 patients were used in the analysis, which compared imidafenacin with propiverine and solifenacin. We found that imidafenacin was effective in treating OAB in our meta-analysis, which was similar to propiverine in its efficacy. The mean number of UI per week (the standardized mean difference (SMD) = 1.23, 95 % CI −0.19 to 2.65, p = 0.09), the mean number of urgency episodes per day (SMD = 0.26, 95 % CI −0.11 to 0.63, p = 0.17), the mean number of micturitions per day (SMD = 0.01, 95 % CI −0.30 to 0.31, p = 0.96), and the mean urine volume (ml) per micturition (SMD = −13.04, 95 % CI −20.45 to −5.62, p = 0.0006) indicated that imidafenacin was similar to propiverine in its efficacy. Mean OABSS (SMD = 0.48, 95 % CI −0.08 to 1.03, p = 0.09) indicated that imidafenacin was also similar to solifenacin in its efficacy. Besides, imidafenacin was better tolerated than propiverine in the safety, indicated by dry mouth (OR 0.73, 95 % CI 0.54–0.98, p = 0.04) and any adverse events (OR 0.63, 95 % CI 0.46–0.88, p = 0.006). Moreover, imidafenacin was also better tolerated than solifenacin in the safety, indicated by constipation (OR 0.21, 95 % CI 0.08–0.53, p = 0.001) and any adverse events (OR 0.33, 95 % CI 0.15–0.71, p = 0.004).

Conclusions

This meta-analysis indicates that imidafenacin was similar to propiverine or solifenacin in its efficacy for OAB and was better tolerated than propiverine or solifenacin in the safety for OAB. We conclude that imidafenacin is preferable to propiverine or solifenacin from a perspective of safety.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Abrams P, Kelleher CJ, Kerr LA et al (2000) Overactive bladder significantly affects quality of life. Am J Manag Care 6(Suppl):S580–S590

    CAS  PubMed  Google Scholar 

  2. Kobelt G, Kirchberger I, Malone-Lee J (1999) Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int 83:583–590

    Article  CAS  PubMed  Google Scholar 

  3. Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327–336

    CAS  PubMed  Google Scholar 

  4. Milsom I, Abrams P, Cardozo L et al (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760–766

    Article  CAS  PubMed  Google Scholar 

  5. Abrams P, Cardozo L, Fall M et al (2002) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 21:167–178

    Article  PubMed  Google Scholar 

  6. Getsios D, El-Hadi W, Caro I et al (2005) Pharmacological management of overactive bladder. Pharmacoeconomics 23:995–1006

    Article  CAS  PubMed  Google Scholar 

  7. Marinkovic SP, Rovner ES, Moldwin RM et al (2012) The management of overactive bladder syndrome. BMJ 344:38–44

    Article  CAS  Google Scholar 

  8. Andersson KE, Chapple CR, Cardozo L et al (2009) Pharmacological treatment of overactive bladder: report from the International Consultation on incontinence. Curr Opin Urol 19:380–394

    Article  PubMed  Google Scholar 

  9. Sexton CC, Notte SM, Maroulis C et al (2011) Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 65:567–585

    Article  CAS  PubMed  Google Scholar 

  10. Chapple CR (2000) Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55:33–46 (discussion 50)

    Article  CAS  PubMed  Google Scholar 

  11. Madhuvrata P, Cody JD, Ellis G et al (2012) Which anticholinergic drugs for overactive bladder syndrome in adults? Cochrane Database Syst Rev 1:005429

    Google Scholar 

  12. Kobayashi F, Yageta Y, Segawa M et al (2007) Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland. Arzneimittelforschung 57:92–100

    CAS  PubMed  Google Scholar 

  13. Kobayashi F, Yageta Y, Yamazaki T et al (2007) Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task. Arzneimittelforschung 57:147–154

    CAS  PubMed  Google Scholar 

  14. Murakami S, Yoshida M, Iwashita H et al (2003) Pharmacological effects of KRP-197 on the human isolated urinary bladder. Urol Int 71:290–298

    Article  CAS  PubMed  Google Scholar 

  15. Homma Y, Yamaguchi T, Yamaguchi O (2008) A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 15:809–815

    Article  CAS  PubMed  Google Scholar 

  16. Homma Y, Yamaguchi O (2009) A randomized, double-blind, placebo- and propiverine controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 16:499–506

    Article  CAS  PubMed  Google Scholar 

  17. Higgins JPT, Green S, (eds) (2011) Cochrane handbook for systematic reviews of interventions, v.5.1 [updated March 2011]. Cochrane Collaboration Web site. http://www.cochrane-handbook.org/

  18. Zaitsu M, Mikami K, Ishida C et al (2011) Comparative evaluation of the safety and efficacy of long-term use of imidafenacin and solifenacin in patients with overactive bladder: a prospective, open, randomized, Parallel-group trial (the LIST Study). Adv Urol 2011:854697

    Article  PubMed Central  PubMed  Google Scholar 

  19. Yokoyama T, Koide T, Hara R et al (2013) Long-term safety and efficacy of two different antimuscarinics, imidafenacin and solifenacin, for treatment of overactive bladder: a prospective randomized controlled study. Urol Int 90(2):161–167

    Article  CAS  PubMed  Google Scholar 

  20. Park C, Park J, Choo MS et al (2014) A randomised, prospective double-blind, propiverine-controlled trial of imidafenacin in patients with overactive bladder. Int J Clin Pract 68(2):188–196

    Article  CAS  PubMed  Google Scholar 

  21. Takeda M, Takahashi S, Nishizawa O et al (2009) Imidafenacin, a novel anticholinergic, significantly improves both nocturia and sleep disorders in OAB patients: ePOCH (Evaluation of anticholinergics in Patients with Overactive bladder and nocturia for Care Health) study. Jpn J Urol Surg 22:53–60

    Google Scholar 

  22. Nagaoka A, Sakurai T, Naito S et al (2011) Sleep disorders and HRQOL were significantly improved by imidafenacin, an anticholinergic agent, in OAB patients with nocturia. Jpn J Urol Surg 24:1649–1656

    Google Scholar 

  23. Shimizu N, Minami T, Uemura H et al (2011) A study of the efficacy and safety of imidafenacin in younger and older elderly patients with overactive bladder. Jpn J Urol Surg 24:639–648

    Google Scholar 

  24. Kuratsukuri K, Tsujimura A, Akino H et al (2012) Randomized controlled trial of nocturia in patients with benign prostatic hyperplasia with OAB using an alpha-blocker combined with a novel anticholinergic, imidafenacin In GOOD-NIGHT Study. Eur Urol (Suppl 11):E745–U584

  25. Shimizu N, Tsujimura A, Akino H et al (2012) Imidafenacin reduces night time urine production as well as increase bladder capacity in nocturia with BPH and concomitant OAB. Results from prospective randomized controlled trial, GOOD-NIGHT study. Abs. 432 ICS

  26. Wada N, Watanabe M, Kita M et al (2012) Effect of imidafenacin on nocturia and sleep disorder in patients with overactive bladder. Urol Int 89(2):215–221

    Article  CAS  PubMed  Google Scholar 

  27. Kase H, Arak S, Kitamura T et al (2010) A comparative study of anticholinergic drugs used for overactive bladder in routine clinical practice, with a focus on dry mouth. Jpn J Urol Surg 23:1299–1306

    Google Scholar 

  28. Homma Y, Yamaguchi O, Imidafenacin Study Group (2008) Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 15:986–991

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors had no conflict of interest to declare in relation to this article.

Author information

Authors and Affiliations

  1. Urology Department, Beijing Tian Tan Hospital, Capital Medical University, No. 6 Tiantan Xi Li, Dong cheng District, Beijing, 100050, China

    Wei Huang, Huantao Zong, Xin Zhou & Yong Zhang

Authors
  1. Wei Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Huantao Zong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xin Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yong Zhang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, W., Zong, H., Zhou, X. et al. Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis. Int Urol Nephrol 47, 457–464 (2015). https://doi.org/10.1007/s11255-015-0916-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-015-0916-1

Keywords

Search

Navigation